GalNAc-Conjugated ApoCIII Antisense Oligomers for Liver-Targeted Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antisense compounds targeting ApoCIII lack potency and efficacy, and there is a need for more effective treatment options for conditions associated with elevated ApoCIII levels, such as cardiovascular disease, metabolic syndrome, obesity, and diabetes.
Innovation Solution
Development of conjugated antisense compounds with a cleavable moiety attached to the 5′ end of an oligonucleotide, utilizing a GalNAc cluster to enhance uptake into liver cells, particularly hepatocytes, and incorporating phosphodiester linkages to improve activity and tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antisense compounds are used to target ApoCIII, then gene expression modulation is achieved, but potency and efficacy are insufficient
Solution Approach 1:
The patent combines an antisense oligonucleotide with a GalNAc cluster conjugate to create a single compound that achieves both gene expression modulation and enhanced liver cell delivery. The GalNAc cluster (multiple N-acetylgalactosamine units) is chemically linked to the antisense oligonucleotide, allowing the compound to simultaneously bind to the ApoCIII mRNA target and be actively transported into hepatocytes via ASGPR receptors, thereby resolving the contradiction between potency and delivery efficiency
Solution Approach 2:
The GalNAc cluster acts as an intermediary that mediates the interaction between the antisense oligonucleotide and the liver cell surface receptors. This intermediary component enables the antisense compound to be recognized and internalized by hepatocytes through the ASGPR pathway, overcoming the limitation of poor cellular uptake that constrained the potency and efficacy of conventional antisense compounds
2Reliability
If higher doses of antisense compounds are administered to improve potency, then gene expression modulation increases, but toxicity and side effects increase
Solution Approach 1:
The GalNAc cluster conjugate introduces local quality enhancement by concentrating the therapeutic effect specifically in liver cells (hepatocytes) where the ApoCIII gene is actively expressed. The ASGPR-mediated delivery mechanism ensures that the antisense oligonucleotide is preferentially delivered to hepatocytes rather than distributing systemically, thereby achieving potent gene expression modulation at the target site while minimizing exposure and potential toxicity in non-target tissues
Solution Approach 2:
The patent uses a cluster of multiple GalNAc units (typically 3-5 units) attached to the antisense oligonucleotide. This clustered configuration creates a high-affinity binding motif that mimics natural ligands for the ASGPR receptor, enabling efficient cellular uptake. The clustering strategy amplifies the delivery effect without requiring proportionally higher doses of the active antisense component, thus improving potency while controlling toxicity
3Ease of manufacture
If conventional antisense compounds are used, then manufacturing is simpler, but tolerability and safety profile are poor
Solution Approach 1:
The patent creates a composite compound by chemically conjugating the GalNAc cluster to the antisense oligonucleotide backbone. This composite structure integrates the gene-silencing function of the antisense oligonucleotide with the liver-targeting function of the GalNAc cluster. The conjugation chemistry uses standard oligonucleotide modification techniques that are compatible with existing manufacturing processes, allowing the composite compound to be synthesized with reasonable complexity while dramatically improving the tolerability and safety profile through enhanced specificity and reduced off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugated antisense compounds demonstrate increased potency and delivery to liver tissue, reduced kidney exposure, and improved tolerability, offering enhanced therapeutic potential for modulating ApoCIII expression.
Implementation Method 1
utilizing a GalNAc cluster to enhance uptake into liver cells, particularly hepatocytes
Implementation Method 2
an antisense compound hybridizes to a target nucleic acid and modulates the amount, activity, and/or function of the target nucleic acid
Implementation Method 3
target mRNA degradation or occupancy-based inhibition. An example of modulation of RNA target function by degradation is RNase H-based degradation of the target PNA upon hybridization with a DNA-like antisense compound
Data Source
AI summary
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Aceteylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat disease, disorders or conditions in an individual in need thereof.